Inhibition of protein kinase Cβ protects against diabetes-induced impairment in arachidonic acid dilation of small coronary arteries

To test the hypothesis that protein kinase C ( PKC) beta-induced reactive oxygen species (ROS) underlie the vascular dysfunction in diabetes, we examined the effects of (S)-13[(dimethylamino)methyl]-10,11-14,15-tetrahydro-4,9: 16,21-dimetheno-1H, 13H-dibenzo[ e, k]pyrrolo[3,4-h][1,4,13]oxadi-azacyclohexadecene1,3( 2H)-dione (LY333531; LY), a specific PKC beta inhibitor, on arachidonic acid (AA)-mediated dilation in small coronary arteries from streptozotocin-induced diabetic rats. This study was designed to determine whether diabetes impairs AA-induced vasodilation of small coronary arteries and whether this defect could be blunted by dietary treatment with LY. Coronary diameter was measured using videomicroscopy in isolated pressurized vessels. In controls, AA dose dependently dilated coronary arteries, with 1 mu M producing 54.7 +/- 3.1% and 30 mu M producing 72.0 +/- 3.0% dilation (n = 9). In diabetic rats, 1 mu M AA only produced 31.4 +/- 3.8% (n = 8; p < 0.01 versus control) and 30 mu M 43.8 +/- 3.7% dilation (n = 8; p = 0.001 versus control). Nitroprusside-mediated vasodilations were similar in control and diabetic rats. In contrast, in diabetic rats receiving LY, AA-mediated coronary dilations were normal. In controls, AA- mediated vasodilation was inhibited by miconazole ( an inhibitor of cytochrome P450 epoxygenase) and by iberiotoxin (IBTX, an inhibitor of the large conductance Ca2+-activated K+ channel), but miconazole and IBTX had no effects in diabetic vessels. In diabetic rats receiving LY, the effects of miconazole and IBTX were similar to control. Superoxide dismutase restored responses to AA in diabetic vessels but had no effect in vessels from control or diabetic rats on LY. These results suggest that AA- mediated vasodilation in rat coronary arteries are impaired in diabetic rats due to increases in generation of ROS. LY protects against these defects in diabetes through inhibition of PKC beta-mediated production of ROS.